P. Regnault

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)

Ulrich Mrowietz, Craig L. Leonardi, Giampiero Girolomoni et al. · Journal of the American Academy of Dermatology · 2015 · 206 citations

Medicine, Dermatology, Immunology +11

Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32‐week results from the randomized placebo‐controlled <scp>TRANSFIGURE</scp> trial

Kristian Reich, John Sullivan, Petr Arenberger et al. · British Journal of Dermatology · 2018 · 101 citations

Medicine, Dermatology, Pharmacotherapy +14

Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5‐year results from the randomized placebo‐controlled TRANSFIGURE study*

Kristian Reich, John Sullivan, Petr Arenberger et al. · British Journal of Dermatology · 2020 · 72 citations

Medicine, Dermatology, Pharmacotherapy +17

Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis

Lin Cai, Xu Yao, Jun Gu et al. · Chinese Medical Journal · 2020 · 48 citations · Full text

Medicine, Dermatology, Pharmacotherapy +12

Sustained efficacy of secukinumab in patients with moderate‐to‐severe palmoplantar psoriasis: 2·5‐year results from <scp>GESTURE</scp> , a randomized, double‐blind, placebo‐controlled trial

Alice B. Gottlieb, Martijn B. A. van Doorn, John Sullivan et al. · British Journal of Dermatology · 2019 · 40 citations

Medicine, Dermatology, Pharmacotherapy +13